Tu Zhen-Hua, Jin Ping-Bo, Chen Di-Yu, Chen Zhi-Yun, Li Zhi-Wei, Wu Jie, Lou Bin, Zhang Bao-Shan, Zhang Lin, Zhang Wei, Liang Ting-Bo
Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, People's Republic of China.
Infect Drug Resist. 2022 May 12;15:2469-2474. doi: 10.2147/IDR.S359919. eCollection 2022.
To evaluate the response and safety of an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) for coronavirus disease 2019 (COVID-19) in liver transplant (LTx) recipients from China.
Thirty-five recipients post LTx from the First Affiliated Hospital of Zhejiang University School of Medicine who received inactivated vaccine from June to October 2021 were screened. Information regarding vaccine side effects and clinical data were collected.
Thirty-five LTx recipients were enrolled, with a mean age of 46 years, and most patients were male (30, 85.71%). All the participants had a negative history of COVID-19 infection. Predictors for negative response in the recipients were interleukin-2 receptor (IL-2R) induction during LTx, shorter time post LTx and application of a derivative from mycophenolate acid (MPA). No serious adverse events were observed during the progress of vaccination or after the vaccination.
LTx recipients have a substantially partial immunological response to the inactivated vaccine for COVID-19. IL-2R induction during LTx, a shorter time post LTx and the application of a derivative from MPA seem to be predictors for a negative serological immunoglobulin G (IgG) antibody response in recipients. The findings require booster vaccination in these LTx recipients.
评估一种灭活疫苗（中国北京科兴生物制品有限公司）对中国肝移植（LTx）受者2019冠状病毒病（COVID-19）的反应及安全性。
筛选了浙江大学医学院附属第一医院35例2021年6月至10月接受灭活疫苗的肝移植术后受者。收集了疫苗副作用及临床数据相关信息。
纳入35例肝移植受者，平均年龄46岁，多数患者为男性（30例，85.71%）。所有参与者既往无COVID-19感染史。肝移植术中白细胞介素-2受体（IL-2R）诱导、肝移植术后时间较短以及应用霉酚酸（MPA）衍生物是受者产生阴性反应的预测因素。接种疫苗过程中及接种后未观察到严重不良事件。
肝移植受者对COVID-19灭活疫苗有显著的部分免疫反应。肝移植术中IL-2R诱导、肝移植术后时间较短以及应用MPA衍生物似乎是受者血清学免疫球蛋白G（IgG）抗体产生阴性反应的预测因素。这些结果提示需要对这些肝移植受者进行加强接种。
